A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Phase 2 Unknown 272 enrolled Gan and Lee Pharmaceuticals, USA

RandomizedParallel-groupOpen-labelTreatment

Summary

This study was a multicenter, randomized, parallel and controlled study in adult patients with T2DM to evaluate the efficacy, safety (including immunogenicity) and pharmacokinetics of GZR18 injection in adult patients with T2DM.

Timeline

Start: 2023-08-09
Primary completion: 2024-07-20
Completion: 2024-07-20

Publications

Liu M, Cheng Z, Lu L, Cai H, Liu J, Liu J, Zheng Y, Wang S, Zhao J, Yang W, Xie T, Li Y, He A, Rodbard HW, Chen W. Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial. Ann Intern Med. 2026 Jun 30. doi: 10.7326/ANNALS-25-04623. Online ahead of print.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bofanglutide	Protein / enzyme biologic	12 mg	Subcutaneous
Subject	Bofanglutide	Protein / enzyme biologic	18 mg	Subcutaneous
Subject	Bofanglutide	Protein / enzyme biologic	24 mg	Subcutaneous
Comparator	Semaglutide	Peptide	1 mg	Subcutaneous

A Study of GZR18 Injection in Chinese Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Publications

Drugs

Indications